1. Home
  2. PNNT vs TRDA Comparison

PNNT vs TRDA Comparison

Compare PNNT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$5.92

Market Cap

423.8M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.74

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNNT
TRDA
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
423.8M
386.8M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
PNNT
TRDA
Price
$5.92
$10.74
Analyst Decision
Hold
Strong Buy
Analyst Count
6
1
Target Price
$6.04
$20.00
AVG Volume (30 Days)
676.0K
183.9K
Earning Date
02-09-2026
02-26-2026
Dividend Yield
15.89%
N/A
EPS Growth
N/A
N/A
EPS
0.50
N/A
Revenue
$122,377,000.00
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.14
P/E Ratio
$12.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.66
$4.93
52 Week High
$7.53
$18.75

Technical Indicators

Market Signals
Indicator
PNNT
TRDA
Relative Strength Index (RSI) 44.56 57.93
Support Level $5.84 $9.87
Resistance Level $6.11 $10.44
Average True Range (ATR) 0.11 0.54
MACD 0.03 -0.13
Stochastic Oscillator 37.88 52.63

Price Performance

Historical Comparison
PNNT
TRDA

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: